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SocietyIntroduction and summary
Hyaluronan (HA) preparations are widely used as intra-ar-
ticular injections1,2 in the treatment of pain associated with
osteoarthritis (OA). A recent meta-analysis has conﬁrmed
that this class is generally safe and treatment effect is sim-
ilar to that of non-steroidal anti-inﬂammatory drugs
(NSAIDs)3. While the precise mechanism(s) of action are
not speciﬁcally deﬁned both biological and physical activi-
ties have been proposed to explain the long-term clinical
beneﬁts that far exceed the pharmacokinetics of HAs in
joints1.
Adverse reactions may include local injection site pain,
but more severe acute inﬂammatory reactions that resem-
ble a septic joint (pseudosepsis) can also occur4e6 espe-
cially upon repeat use. To date, published reports have
been associated primarily with injections of the chemically
cross-linked HA, hylan GF-20, and there have been no pub-
lished reports using the sodium hyaluronate preparations
approved for use in the US. In addition, there have been
chronic granulomatous reactions7,8 that have been pro-
posed to be part of a continuum of pathologies associated
with reactions to hylan injections.
This study was designed to examine effects of a 5-week
course of intra-articular injections of sodium hyaluronate
(M.W. 500e730 kDa; Hyalgan) on synovial ﬂuid (SF) fea-
tures and synovial biopsies in eight patients with OA of the
knee. Our objectives were to search for evidence that might
help to clarify mechanisms of action, and to identify whether
there was any histopathological evidence that this avian
derived sodium hyaluronate may elicit inﬂammatory granu-
lomatous reactions following intra-articular injections.
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anti-inﬂammatory effects of hyaluronic acid nor do they
show any altered presence of intracellular HA as assessed
by uridine diphosphoglucose dehydrogenase (UDPGD)
staining. They do support the notion that sodium hyaluro-
nate (M.W. 500e730 kDa) does not elicit any signiﬁcant his-
topathological changes or inﬂammation following ﬁve
weekly injections of 20 mg (2 ml).
Methods, results and discussion
Eight clinically stable patients with OA of the knee meet-
ing American College of Rheumatology (ACR) criteria9 and
having Kellgren grade 2 and 3 radiographic changes were
included in this open-label study which was approved by
the IRB at the Philadelphia VA Medical Center. Each patient
willing to undergo biopsies, was evaluated, had joint ﬂuid
aspirated and a needle synovial biopsy on the ﬁrst visit
just before treatment with sodium hyaluronate and 1 week
after the ﬁfth visit. Patients were scored for pain on walking
on a 10-point visual analog score.
After aspiration of any joint effusion, blind needle synovial
biopsy was performed using a supero lateral approach and
a ParkerePearson needle as previously described10. We
performed routine SF analysis on all effusions obtained.
Several aspirations yielded no ﬂuid. Approximately 10
specimens of synovial tissue were taken from each patient
with 3 to 4 ﬁxed in formalin for parafﬁn embedding and
stained with hematoxylin and eosin. Other tissue was
snap frozen in OCT and used for staining for the HA
associated enzyme, UDPGD, with methods used by
El-Gabalawy et al.11. Freshly cut 8 mm frozen sections on
polyacrylamide coated slides were kept in a desiccator for
up to 1 h. Reaction media were applied to slides and
contained 0.3 mg/ml NAD, 3 mg/ml NBI, and 25% (wt/vol)
polyvinyl alcohol in 0.05 M glycl-glycine buffer (pH 7.8).
Slides were placed in anaerobic chamber (‘‘ziplock’’ bag
evacuated of room air and instilled with N gas) and
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Patient
ID
Fibrin SLC
(layers)
Lymphocytes Vascular
congestion
Vessels
#/HPF
FTC Fibrosis Other UDPGD Walking
pain VAS
SF
(WBC/mm3)
1 1 1e2 1þ 0 6e10 0 0  2.1 200
2 1e2 2þ 3þ 2e20 1þ 0 Thrombosed
vessels
þ 6.4 150
2 1 2e5 1þ 2þ 10e15 1þ 1þ Scarred vessel
sites
þ 9.1 200
2 2e4 1þ 2þ 10e20 1þ 0 þ 9.0 150
3 1 1e2 0 1þ 5e10 1þ 1þ  5.5 N
2 1e2 1þ 0 6e10 1þ 1þ  2.5 N
4 1 2e4 1þ 1þ 5e15 1þ  2.7 N
2 1e3 1þ 1þ 3e5 þ 0.4 N
5 1 2e6 2þ 0 3e5 2þ Hemosiderin 3.5 50
2 1 0 0 2e3 1þ  1.7 50
6 1 3e4 1þ 1þ 2e8 Occasional plasma
cells
þ 7.3 100
2 1e10 1þ 1þ 2e3 1þ 1 0.8 100
7 1 2e3 1þ 1þ 6e8 þ 9.3 50
2 1e5 1þ 2þ 6e10 0 0 þ 3.0 N
8 1 2e5 0 0 10e15  8.1 150
2 1e5 0 0 5e15  2.4 N
SLC¼ Synovial lining cells. FTC¼ Fixed tissue cells. Qualitative scores for ﬁbrin, lymphocytes, vascular congestion, FTC and ﬁbrosis
range from 0¼ none to 3þmaximum presence. Walking pain was recorded on a 10-point visual analog scale (VAS). N¼No ﬂuid obtained.incubated at 37(C for 45 min. The medium was removed,
glycergel applied and the slide covered. A positive result
showed blue staining. Positive and negative controls
(NAD omitted) were done simultaneously for each sample.
All slides were examined and scored blindly (without
knowledge of patient or temporal relationship of specimen)
by HRS (H & E) or CAH (special stains). Layers of lining
cells and vessels/HPF were recorded. Other routine histo-
logical features were described semiquantitatively as
0e3þ.
There were no changes in SF leukocyte counts with all
remaining in the ‘‘non-inﬂammatory’’ range with counts of
300/mm3 or less (Table I).
Histologic evidences of some at least focal hyperplasia of
synovial lining cells and mild mononuclear inﬂammation
were seen in virtually all patients. No pattern suggested
any signiﬁcant changes between biopsies. Importantly, no
granulomatous reactions were seen. There was no pattern
of change in UDPGD staining.
The presence of mild inﬂammation in these OA synovial
biopsies was not unexpected as this has been well docu-
mented in many studies including the work by Haywood
et al.12, in our own laboratory13, and Oehler et al.14. This
was not reﬂected by SF leukocyte counts that fell well within
the normal range. There was no detectable increase or de-
crease in cell counts after the HA therapy. The histologically
detected mild inﬂammation in the synovium did not change
after treatment. Listrat et al.15 have performed arthroscopy
after up to nine HA (sodium hyaluronate, M.W.
500e730 kDa) injections over 1 year but focused on carti-
lage and not synovium. Cartilage change seemed less
with the HA than in controls. Pasquali-Ronchetti et al.16 ex-
amined synovial biopsies obtained by arthroscopy before
and 6 months after a 5-week course of sodium HA, M.W.
500e730 kDa. They reported signiﬁcant decreases in the
number of lining cells, macrophages, lymphocytes, mast
cells, and ﬁbrin with more ﬁbrocytes and ﬁbrosis. Similar im-
provement was reported 6 months after intra-articular meth-
ylprednisolone. No deleterious effect of either type injection
was reported. Since clinical improvement is often delayed
for weeks after a course of HA injections it is possible thathistologic improvement in our patients might have been
shown with examination later. Most of our patients did
have less pain on walking 1 week after the ﬁfth injection
at the time of the biopsies. All patients studied by Pas-
quali-Ronchetti had arthroscopy with lavage which could
have had some beneﬁcial effect.
One concern has been whether synovitis can actually
be accentuated in some patients by HA injections. As not-
ed before, we and others4e6 reported that acute pseudo-
septic ﬂares can be seen in a small percentage of
patients after hylan GF-20 injections. Most of the reactions
of this type have followed hylan GF-20 injections. A single
report using a fermented sodium hyaluronate has recently
been published4. Chen et al.7 reported granulomatous in-
ﬂammation surrounding alcian blue stained material in
synovium in six patients who were still symptomatic at sur-
gery after hylan GF-20 injections. Michou et al.8 have also
noted two cases with granulomatous synovitis after the
second and third intra-articular injections of hylan GF-20.
Recently Sasaki et al. have also reported that they have
been able to reproduce reactions with hylan GF-20 but
not with sodium hyaluronate preparations following injec-
tions into mice, rabbits and guinea pigs17,18. Schiavinato
et al.18 have injected rabbit joints with single or three
weekly 500e730 kDa HA doses and examined synovial
histology at 6, 16, and 48 h and reported no histologic ab-
normalities. In contrast, rabbits injected with cross-linked
hylan GF-20 had no inﬂammation after single injections
but had varying degrees of inﬂammation including some
alcian blue positive surface deposits after three injections.
No similar reactions have been seen in our biopsies in
eight patients.
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